SAB Biotherapeutics Inc
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune… Read more
SAB Biotherapeutics Inc (SABS) - Total Liabilities
Latest total liabilities as of September 2025: $18.37 Million USD
Based on the latest financial reports, SAB Biotherapeutics Inc (SABS) has total liabilities worth $18.37 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
SAB Biotherapeutics Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how SAB Biotherapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
SAB Biotherapeutics Inc Competitors by Total Liabilities
The table below lists competitors of SAB Biotherapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Unimot S.A
WAR:UNT
|
Poland | zł2.70 Billion |
|
Cystech Electronics Corp
TWO:6651
|
Taiwan | NT$352.87 Million |
|
TBS Energi Utama Tbk PT
JK:TOBA
|
Indonesia | Rp568.14 Million |
|
EREUF
PINK:EREUF
|
USA | $224.87 Million |
|
HI Mobility Berhad
KLSE:5335
|
Malaysia | RM234.96 Million |
|
Axactor SE
OL:ACR
|
Norway | Nkr930.72 Million |
|
5QQ
F:5QQ
|
Germany | €597.72 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down SAB Biotherapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SAB Biotherapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SAB Biotherapeutics Inc (2019–2024)
The table below shows the annual total liabilities of SAB Biotherapeutics Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $18.23 Million | -31.59% |
| 2023-12-31 | $26.64 Million | +34.24% |
| 2022-12-31 | $19.85 Million | -53.40% |
| 2021-12-31 | $42.59 Million | +142.96% |
| 2020-12-31 | $17.53 Million | -13.68% |
| 2019-12-31 | $20.31 Million | -- |